CortheraBio

Sepantronium Bromide (PC-002)

Cothera’s lead program PC-002 is a first-in-class small molecule drug targeting Myc-mutated tumors.  With more than 50% of human cancers showing increased expression, Myc is regarded as one of the most important yet “undruggable” cancer targets.  With a unique mechanism of action, PC-002 selectively induces Myc protein degradation and cell apoptosis in Myc-dependent tumors, potentially targeting multiple indications in cancers involving Myc dysregulation.

PC-002 program is currently in Phase 2 clinical studies for multiple indications, including high-grade lymphoma in patients with c-MYC translocation (NCT05263583) as well as neuroendocrine prostate cancer in patients with n-MYC abnormality.

CortheraBio
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.